Merrimack Pharmaceuticals Announces $225M Milestone Payment and Liquidating Dividend Plans
Wednesday, 27 March 2024, 20:36
Key Points:
Merrimack Pharmaceuticals receives a $225 million milestone payment from Ipsen.
Details:
- This payment follows the FDA approval of a treatment
- The company plans to distribute a liquidating dividend to stockholders
Conclusion: The significant payment from Ipsen signifies a positive development for Merrimack Pharmaceuticals, bolstering its financial standing and rewarding stockholders with a liquidating dividend.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.